Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer

13 Jul 2017

Abstract excerpt

sst5TMD4, a splice variant of the sst5 gene, is overexpressed and associated with aggressiveness in various endocrine‐related tumors, but its presence, functional role, and mechanisms of actions in prostate cancer (PCa)—the most common cancer type in males—is completely unexplored. In this study, formalin‐fixed, paraffin‐embedded prostate pieces from patients with localized PCa, which included tumoral and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Fibroblast Growth Factor Research
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28705809
DOI: 10.1096/fj.201601264rrr

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancerPMID 28705809Read ↗

The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells.Semantic proximity Read ↗

The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients.Semantic proximity Read ↗

Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapse.Semantic proximity Read ↗

Association between somatostatin receptor 5 gene polymorphisms and pancreatic cancer risk and survival.Semantic proximity Read ↗

A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing-tumor as a potential target of peptide receptor imaging and therapySemantic proximity Read ↗

Genetic variation in the SST gene and its receptors in relation to circulating levels of insulin-like growth factor-I, IGFBP3, and prostate cancer risk.Semantic proximity Read ↗

Epigenetic and post‐transcriptional regulation of somatostatin receptor subtype 5 (SST 5 ) in pituitary and pancreatic neuroendocrine tumorsSemantic proximity Read ↗

Somatostatin Receptor 2 Overexpression in Hepatocellular Carcinoma: Implications for Cancer Biology and Theranostic ApplicationsSemantic proximity Read ↗

Pituitary Adenoma: SSTR2 rs2236750, SSTR5 rs34037914, and AIP rs267606574 Genetic Variants, Serum Levels, and Ki-67 Labeling Index Associations.Semantic proximity Read ↗

Impact of GAS5 genetic polymorphism on prostate cancer susceptibility and clinicopathologic characteristics.Semantic proximity Read ↗

Truncated somatostatin receptors as new players in somatostatin–cortistatin pathophysiologySemantic proximity Read ↗

A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.